ELE-101 Safety & Tolerability Study

• Research type

  Research Study

• Full title

  A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants.

• IRAS ID

  1004278

• Contact name

  Nicola Kidman

• Contact email

  nicola.kidman@eleusisltd.com

• Sponsor organisation

  Beckley Psytech Ltd (Beckley) - Joint Sponsor

• Eudract number

  2022-000150-29

• Clinicaltrials.gov Identifier

  NCT05434156

• Research summary

  The purpose of this study is to test a drug called ELE-101 that is being developed as a potential therapeutic treatment of depression

• REC name

  Wales REC 1

• REC reference

  22/WA/0100

• Date of REC Opinion

  6 Jun 2022

• REC opinion

  Further Information Favourable Opinion